Optivia Inks Drug-Interaction Collaboration with FDA

Feb 01, 2011

NEW YORK (GenomeWeb News) – Optivia Biotechnology today said that it will collaborate with the US Food and Drug Administration on identifying potentially harmful drug-dietary supplement interactions.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

FDA Approves Abbott's Molecular CMV Assay
Bidens Launch Cancer Initiative to Preserve Momentum, Push Forward Moonshot Priorities
Prostate Cancer Recurrence Signatures Proposed From MicroRNA Meta-Analysis
NCI Announces Centers Participating in Third Stage of Clinical Proteomic Tumor Analysis Project
Sema4, GNS Healthcare Collaborate on Machine Learning for Therapy Discovery
DuPont Pioneer Licenses CRISPR Tech From ERS Genomics

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

Main menu